Senseonics Inc

Senseonics Safety Information eversensediabetes.com/safety…

Senseonics Announces a Positive Coverage Decision for Eversense CGM From Humana bit.ly/2WdzN3A

Senseonics Announces a Positive Coverage Decision for Eversense CGM from Health Care Service Corporation - Blue Cross Blue Shield of Illinois, Montana, New Mexico, Oklahoma and Texas bit.ly/2MJbR40

Senseonics Announces the Completion of US Patient Enrollment in the PROMISE 180-Day Sensor Clinical Study bit.ly/2nAr9PM

Are you living with diabetes, or know someone who is? Do you have a desire to help others learn more about the day-to-day life with diabetes? Be sure to check out our community page. bit.ly/2MG5DEi

Are you living with diabetes, or know someone who is? Do you have a desire to help others learn more about the day-to-day life with diabetes? Be sure to check out our community page. bit.ly/2MG5DEi

Senseonics Announces Two Positive Blue Cross Blue Shield Coverage Decisions for Eversense CGM bit.ly/34n2gYI

Real-World Experience of Repeat Users Shows Long-Term Safety of the Implantable Eversense CGM System in the Home-Use Setting bit.ly/3484NWe

Senseonics Publishes Eversense® CGM Real-World Data from First U.S. Users bit.ly/2No2Cbf

Join us August 28th & 29th for one of two Facebook LIVE events with our Eversense Unstoppable Ambassadors: news anchor Darrell Greene @t1d_g, powerlifter Chris Ruden @chrisruden and author Laura Kronen @beyouonlybetter Register here: bit.ly/2N2jeVP

All About the Eversense XL Continuous Glucose Monitor (CGM) bit.ly/2Mf1IOA

If you are attending AADE in Houston next week be sure to visit us in Booth #1300. #AADE2019 bit.ly/2O60lP5

Geo-Med and The Veterans Affairs Medical Center in Omaha, Nebraska is the first VA in the country to offer EversenseCGM. Now, veterans with diabetes in Omaha (and across the country) can experience the freedom of using an up to 3-month CGM system. #CGM ... bit.ly/2Mh4z8T

If you missed the talk on User Acceptance of the Eversense® CGM System in a Home Use Setting: The House Study by Dr. Magnus Londahl at ADA 2019, you can read the abstract here: bit.ly/2XAtNGg

If you missed the poster sessions at ADA, click the link below to view the abstract: Post Market Clinical Follow-Up (PMCF) Registry to Demonstrate the Long Term Safety of the Eversense CGM System, that was presented at 2019 ADA. bit.ly/2S6PWGi

Senseonics Announces FDA Approval for a Non-Adjunctive Indication (Dosing Claim) for the Eversense® 90-day CGM System bit.ly/2EVKgJR #Senseonics #EversenseCGM